Full Press Release Details
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
June 23, 2026
NXL Positive Sentiment Score: 75/100
Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device
Key Takeaway: Nexalin Technology has announced that the investigator of its Brazilian clinical trial has received the Young Researcher Award at BRAIN 2026. This recognition is for research evaluating the company's proprietary DIFS™ platform, which is linked to their Gen-2 tACS device. The positive results from the clinical study are expected to enhance the company's reputation in the biopharma sector.
Price reaction · baseline $1.32 (2024-04-17 close) · hit pre-market · clean, no other NXL news in the window
day 0 close
+11.4%
day 1
+8.3%
day 3 · peak
+23.1%
Market Sentiment Analysis
POSITIVE FACTORS
- Nexalin Technology's clinical trial results are well-received.
- The investigator's recognition highlights the significance of the research.
- The award indicates a strong contribution to the field of research.
Frequently Asked Questions
What award did the investigator receive?
The investigator received the Young Researcher Award at BRAIN 2026.
What is the focus of the clinical trial?
The clinical trial evaluates Nexalin's proprietary DIFS™ platform.
What device is associated with the clinical study?
The study is associated with Nexalin's Gen-2 tACS device.
When was the announcement made?
The announcement was made on June 23, 2026.